Technical University of Munich (TUM)
Technische Universität München (TUM)

Germany

The Technical University of Munich (TUM) is one of Europe’s leading universities in research and teaching. As the Entrepreneurial University, it doesn’t just want to understand the world – it wants to improve it. That is why the entire university revolves around one core goal: innovation.

Interdisciplinary solutions to future challenges

TUM’s unparalleled range of disciplines covers engineering and natural sciences, life sciences and medicine, management and social sciences – a combination found nowhere else in Europe. TUM leverages this enormous potential by intensively and intelligently combining the different subjects. This inspires modern fields of research extending from bioengineering to machine intelligence. At the same time, TUM links technological change more closely with social, political and ethical issues than other technical university.
www.tum.de

Excellent career prospects for graduates

Its outstanding degree programs are strongly oriented towards research and, at the same time, tightly coupled to practical experience. Managers regularly choose TUM as one of the 10 best universities worldwide for the quality of graduates. (Global Employability University Rankings)

TUM offers amazing opportunities at every level of study and research – starting with the first semester right through to professorship. It invests more than other universities in the professional development of individual talent.
www.tum.de/studies

Awakening the entrepreneurial spirit

No other German university produces more start-up founders – the result of a support infrastructure unrivalled in Europe. TUM also builds long-term research partnerships with the most innovative global players. More and more companies are establishing roots directly on campus.

A global university

TUM is an international university with a high proportion of foreign students and researchers as well as more than 150 partner universities around the globe. With the founding of TUM Asia in 2012 in Singapore, it became the first German university to establish an overseas campus. TUM also has offices in Brussels, Cairo, Mumbai, Beijing, San Francisco, and São Paulo.
www.tum.de/global

Among the top

TUM was awarded the title of “University of Excellence” in 2006 and 2012 in recognition of its innovative, dynamic culture. Far from resting on its laurels, though, TUM remains entrepreneurial – constantly striving to reach new heights.
www.exzellenz.tum.de

Portrait: Technical University of Munich – 150 Years culture of excellence

1 November 2017 - 31 October 2018

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for Technical University of Munich (TUM) published between 1 November 2017 - 31 October 2018 which are tracked by the Nature Index.

Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

AC	FC
486	132.68

Outputs by subject (FC)

Subject	AC	FC
Earth & Environmental Sciences	27	7.27
Life Sciences	188	31.02
Physical Sciences	195	55.51
Chemistry	142	60.82

Highlight of the month

Combo drug strategy for cancer

Targeting a critical signalling protein called SHP2 may augment the anti-tumour effects of a promising class of approved drugs known as MEK inhibitors.

A team led by Technical University of Munich researchers studied mouse models of lung and pancreatic cancer driven by altered forms of KRAS, a gene found mutated in many patients with these tumour types.

When the researchers blocked the activity of SHP2, either by genetic or pharmacological means, they saw delays in cancer progression.

SHP2 inhibition helped reduce levels of the mutant KRAS protein, but the treatment alone was insufficient to induce tumour regression. Only by adding an additional MEK-targeted drug could the researchers achieve tumour shrinkage in the mouse models. The synergistic drug combination also cut the risk of tumours developing resistance to the MEK inhibitor.

The findings highlight a compelling dual-drug strategy that merits further testing in clinical trials.

Supported content